Sunshine Biopharma (NASDAQ:SBFM) vs. Evolus (NASDAQ:EOLS) Head to Head Review

Evolus (NASDAQ:EOLS – Get Free Report) and Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for Evolus and Sunshine Biopharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolus 1 1 4 0 2.50
Sunshine Biopharma 1 1 0 0 1.50

Evolus presently has a consensus target price of $15.00, suggesting a potential upside of 119.14%. Given Evolus’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Evolus is more favorable than Sunshine Biopharma.

Profitability

This table compares Evolus and Sunshine Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evolus -9.56% N/A -11.10%
Sunshine Biopharma -18.89% -26.55% -21.30%

Valuation and Earnings

This table compares Evolus and Sunshine Biopharma”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evolus $297.18 million 1.52 -$51.64 million ($0.47) -14.56
Sunshine Biopharma $35.35 million 0.02 -$5.97 million ($170.20) -0.02

Sunshine Biopharma has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Evolus has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Institutional & Insider Ownership

90.7% of Evolus shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Comparatively, 0.4% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Evolus beats Sunshine Biopharma on 12 of the 14 factors compared between the two stocks.

About Evolus

(Get Free Report)

Evolus, Inc. is a medical aesthetics company focused on developing and commercializing treatments for cosmetic procedures. The company’s portfolio includes injectable products used by healthcare professionals to address facial lines and wrinkles and to enhance facial appearance. Its flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is a prescription botulinum toxin treatment for moderate to severe frown lines between the eyebrows in adults. Evolus also markets Evolysse, a line of hyaluronic acid dermal fillers designed for facial aesthetic treatments.

About Sunshine Biopharma

(Get Free Report)

Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.